0000899243-23-006730.txt : 20230302
0000899243-23-006730.hdr.sgml : 20230302
20230302160534
ACCESSION NUMBER: 0000899243-23-006730
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230228
FILED AS OF DATE: 20230302
DATE AS OF CHANGE: 20230302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zeng Ling
CENTRAL INDEX KEY: 0001824252
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40657
FILM NUMBER: 23698837
MAIL ADDRESS:
STREET 1: C/O DICERNA PHARMACEUTICALS, INC.
STREET 2: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Omega Therapeutics, Inc.
CENTRAL INDEX KEY: 0001850838
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 20 ACORN PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
BUSINESS PHONE: (617) 949-4360
MAIL ADDRESS:
STREET 1: 20 ACORN PARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-28
0
0001850838
Omega Therapeutics, Inc.
OMGA
0001824252
Zeng Ling
C/O OMEGA THERAPEUTICS, INC.
20 ACORN PARK DRIVE
CAMBRIDGE
MA
02140
0
1
0
0
See Remarks
Option (Right to Buy)
6.46
2023-02-28
4
A
0
55000
0.00
A
2033-02-27
Common Stock
55000
55000
D
The options vest and become exercisable with respect to 25% of the underlying shares on February 28, 2024 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 28, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Chief Legal and Administrative Officer
/s/ Barbara Chan as Attorney-in-Fact for Ling Zeng
2023-03-02